Floatz logo

Isatuximab

Non-Hodgkin Lymphoma

Indapta Therapeutics, INC.monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

372 Active assets in the Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclosporin A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Pegaspargase
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Adriamycin
National Cancer Institute (NCI)
Phase 4BBB
Prednisolone
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

Isatuximab is also rated in:

plasma cell myelomaActive
BB
Indicative · Phase 4
68 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
B
Indicative · Phase 2
57 / 100
View asset →
lymphomaActive
B
Indicative · Phase 2
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →